This study was designed as a pilot study to test the feasibility and efficacy of administering a dose-intense version of a standard combination chemotherapy regimen ProMACE-CytaBOM for patients with stages II, III, and IV diffuse aggressive lymphoma and stages III and IV follicular mixed lymphoma. The treatment consists of eight 2-week cycles, for a total of sixteen weeks. A dose escalation schema has been added and most patients are able to be escalated to dose level three. To date, there have been 81 evaluable patients entered on study: 69 have achieved a complete response (85%). There have been 14 relapses, all following short complete remissions. These preliminary results indicate that the treatment can be safely given, though some patients require dose-reductions. Response rates are equivalent to standard ProMACE-CytaBOM.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01CM009336-06
Application #
3752486
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Division of Cancer Treatment
Department
Type
DUNS #
City
State
Country
United States
Zip Code